Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
oleh: Lorenz Kocheise, Lorenz Kocheise, Ignazio Piseddu, Ignazio Piseddu, Joscha Vonderlin, Joscha Vonderlin, Eric T. Tjwa, Eric T. Tjwa, Gustav Buescher, Gustav Buescher, Lucy Meunier, Lucy Meunier, Pia Goeggelmann, Francesca Fianchi, Francesca Fianchi, Jérôme Dumortier, Jérôme Dumortier, Mar Riveiro Barciela, Mar Riveiro Barciela, Tom J. G. Gevers, Tom J. G. Gevers, Tom J. G. Gevers, Benedetta Terziroli Beretta-Piccoli, Benedetta Terziroli Beretta-Piccoli, Benedetta Terziroli Beretta-Piccoli, Benedetta Terziroli Beretta-Piccoli, Maria-Carlota Londoño, Maria-Carlota Londoño, Sona Frankova, Sona Frankova, Thomas Roesner, Vincent Joerg, Vincent Joerg, Constantin Schmidt, Constantin Schmidt, Fabian Glaser, Fabian Glaser, Jan P. Sutter, Jan P. Sutter, Thorben W. Fründt, Thorben W. Fründt, Ansgar W. Lohse, Ansgar W. Lohse, Samuel Huber, Samuel Huber, Johann von Felden, Johann von Felden, Marcial Sebode, Marcial Sebode, Kornelius Schulze, Kornelius Schulze
| Format: | Article |
|---|---|
| Diterbitkan: | Frontiers Media S.A. 2024-01-01 |
Deskripsi
Subjek
autoimmune disease (AID); immune checkpoint inhibitors (ICI); autoimmune liver diseases (AILD); immune related adverse effects (irAEs); PD-1/PD-L1 immune checkpoint inhibitors; autoimmune hepatitis (AIH)